Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment
Authors:
- Jennifer A. GrossJGJennifer A. Gross
- Barry NevinBNBarry Nevin
- Nicole UrbanNUNicole Urban
- Nathalie SchollerNSNathalie Scholler
- 1 October 2007
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 255 (2) , 263-274
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discoveryCancer Letters, 2007
- Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumorsMolecular Cancer, 2006
- Soluble Mesothelin–Related Peptides in the Diagnosis of Malignant Pleural MesotheliomaAmerican Journal of Respiratory and Critical Care Medicine, 2006
- The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsiesHistopathology, 2006
- Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian CancerClinical Cancer Research, 2006
- Mesothelin Is Overexpressed in Pancreaticobiliary Adenocarcinomas but Not in Normal Pancreas and Chronic PancreatitisAmerican Journal of Clinical Pathology, 2005
- Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell AdhesionJournal of Biological Chemistry, 2004
- Mesothelin-family proteins and diagnosis of mesotheliomaThe Lancet, 2003
- Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinomaProceedings of the National Academy of Sciences, 1999
- Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.Proceedings of the National Academy of Sciences, 1996